Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations QGE031 - Anti-IgE Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04210843 (CQGE031C2302E1) Chronic spontaneous urticaria Phase 3 800 The proportion of subjects with well-controlled disease (UAS7 ≤ 6) at week 12 Ligelizumab Dose 1 and 3 Ligelizumab Dose 2 and 3 Patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 Read-out Milesstone(s) 2026 Publication Study design presented at 2020 EAACI NCT02649218 (CQGE031C2201E1) Chronic spontaneous urticaria Phase 2 226 Long-term safety; number of participants with treatment-emergent adverse events Ligelizumab 240 mg q4wks open label for 52 weeks Adult patients with chronic spontaneous urticaria inadequately controlled with H1- antihistamines at approved or increased doses, alone or in combination with H2- antihistamines or leukotriene receptor antagonists. 2019 (actual) Manuscript: Primary results extension trial (JAMA), H2 2021 83 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation